Nav: Home

First 'targeted' treatment for small cell lung cancer shows promise

September 28, 2015

Vienna, Austria: Small cell lung cancer (SCLC) is an aggressive disease that is difficult to treat and is frequently only diagnosed when it has spread to other parts of the body (metastasised). Five-year survival rates in SCLC, which accounts for about 14% of all lung cancers, are very low, at only six percent. But today US researchers will present two novel findings with important implications for treatment at the 2015 European Cancer Congress [1].

Dr M. Catherine Pietanza, MD, an Assistant Attending Physician at the Memorial Sloan Kettering Cancer Center, New York, USA, will report on results from a phase I trial of a novel agent, rovalpituzumab tesirine (Rova-T, or S16LD6.5), in 79 patients with SCLC who had progressed after first line (given when the disease is newly diagnosed) or second line therapy (given when the disease progresses or recurs).

"While other cancers have multiple treatment options, there is only one agent approved in SCLC, and none available in the third line setting; the outlook for these patients is dismal," she will say. Third line therapy is given after first and second line treatments have failed to halt the progression of disease.

The patients ranged in age from 44-81, with a median age of 62 years. As is normal in phase I trials, they received escalating doses of Rova-T once every three weeks until toxicity reached a point at which the increase in dose needed to be stopped. The drug was designed to bind to DLL3 (delta like protein 3), a protein that is highly expressed in approximately 70% of SCLCs.

"Of the 48 tumour samples we were able to analyse, 33 were positive for DLL3. Among the 29 DLL3+ patients we could treat at the maximum tolerated dose of Rova-T, ten (34%) had a partial response and nine (31%) had disease stabilisation. The duration of response among these patients was more than 178 days, with no cases of disease progression," Dr Pietanza will say.

Rova-T is an antibody drug conjugate (ADC) consisting of three components - an antibody, a linker and the active chemotherapy, or cytotoxic payload. The antibody portion of an ADC can recognise cell surface receptors specific to and that are over-expressed in cancer cells, allowing the delivery of the chemotherapy directly to the tumour. This means the treatment is more effective, and also minimises its exposure to normal cells, with a consequent reduction in toxicity.

"The high response rate is exciting in itself, and above that we have been able to identify a biomarker for SCLC in DLL3+, thus enabling us to 'target' treatment in SCLC. The activity of the drug that we have seen is remarkable, and importantly, the durable, long-term responses are notable in such an aggressive disease where progression is normally very rapid," says Dr Pietanza.

Whereas the most common treatment for early stage NSCLC is surgery, SCLC is not usually diagnosed in time for this to be a viable possibility, and chemotherapy is the standard of care. It remains a worldwide public health problem, since it is associated with exposure to tobacco smoke, and it is a major cause of death from cancer. Currently, standard first line therapy is the chemotherapy combination etoposide/platinum, which is combined with radiation therapy to the chest in limited stage disease, and second line chemotherapy consists of topotecan. Because SCLC can spread quickly to the brain, cranial radiation therapy may also be given.

"The first line therapy has not changed for four decades, and there is no third line treatment at present, so it is clear that Rova-T is likely to fulfil an unmet need for these patients. I would like to see additional, larger trials to develop it further in settings where there is a clear need in this disease. We are looking forward to further assisting in its development and to gaining a better understanding of its value in all cases of SCLC," Dr Pietanza will conclude.

Professor Peter Naredi, the ECCO scientific co-chair of the Congress, who was not involved in the research, commented: "Dr Pietanza's presentation underlines once again how exciting this Congress is. Not only have we had reports of the large-scale efficiency of checkpoint inhibitors in many tumour types, but Dr Pietanza reports remarkable early results of rovalpituzumab tesirine, a drug designed to bind to DLL3, a protein that is highly expressed in approximately two-thirds of SCLCs, a disease where we have seen no novel treatment options for many years.

"I was pleased to see that in patients who were DLL3 positive a majority had long lasting stable disease or partial response. It will be exciting to follow further phase II and III trials of this treatment."
Abstract no: LBA 7. "Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC)", Presidential session III, 14.35-17.25 hrs (CEST), Monday 28 September, Hall D1 (presenting at 15.45 hrs).

[1] The European Cancer Congress is the 18th congress of the European CanCer Organisation (ECCO) and the 40th congress of the European Society for Medical Oncology (ESMO).

ECCO-the European CanCer Organisation

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".